Pilot Study for High Output Drainage Removal After Gastrectomy

Official title

A Pilot Study Comparing the Incidence of Intra-abdominal Complications According to the Removal of the Drainage Tube in Patients With Large Amounts of Drainage After Gastrectomy in Gastric Cancer Patients

Overview

\*Objective: The study aims to evaluate whether there is a difference in intra-abdominal complication rates between patients discharged with or without a drainage tube following gastrectomy with high postoperative drainage (≥300ml/day). \*Study Design: This is an open-label randomized controlled trial (RCT) involving two groups. Patients will be randomly assigned to either maintain the drainage tube (control) or have it removed (experimental) before discharge. The primary endpoint is the incidence of intra-abdominal complications within one month post-surgery. \*Participants: The study targets 60 patients (30 per group) who meet the following criteria: Diagnosed with gastric adenocarcinoma and underwent curative gastrectomy (R0 resection). Postoperative drainage of 300-500 ml/day on the 4th day after surgery. Patients with stage IV cancer, peritoneal metastasis, or postoperative complications requiring additional intervention are excluded. \*Methods: All participants will follow standard postoperative care except for the removal or retention of the drainage tube. Follow-up will occur at 1 and 3 weeks post-discharge, with clinical examinations and imaging (if necessary) to monitor for complications such as infection or abscess. The study's total observation period will last four weeks from the surgery date. \*Data Collection: Data will include patient demographics, surgical details, postoperative management, and the occurrence of complications. Drainage volumes will be recorded daily for those discharged with a tube, and tube removal will occur based on specific criteria.

Interventions

• Procedure Arm I (Drainage tube removal)
  During gastrectomy, a drainage tube is placed within the abdominal cavity. In Arm I (the intervention group), the drainage tube will be removed at the bedside. This procedure is a simple intervention that does not require local anesthesia and involves the removal of the drainage tube by cutting the nylon suture.

Primary outcome measures

• Incidence of Intra-Abdominal Complications [Time frame: up to 1 month]

Secondary outcome measures (2)

• Drain-Related Complications [Time frame: up to 1month]
• CRP Level Changes [Time frame: up to 1month]

Eligibility criteria

Inclusion criteria

• Patients pathologically diagnosed with gastric adenocarcinoma before surgery.
• Patients eligible for complete surgical resection (R0 resection).
• Patients with an ASA (American Society of Anesthesiologists) score of 3 or lower.
• Patients with more than 300 ml of drainage in the 24 hours on the postoperative day 4.

Exclusion criteria

• Patients aged 80 or older.
• Patients with stage IV gastric cancer.
• Patients with ascites due to peritoneal metastasis.
• Patients with evident intra-abdominal complications following surgery.
• Patients who require the insertion of additional percutaneous drainage due to insufficient drainage.
• Patients who underwent incomplete gastric resection (R1 or R2 resection).
• Patients diagnosed with cancers other than gastric cancer.
• Patients with a history of major intra-abdominal surgery or abdominal radiotherapy that may hinder the normal absorption of intra-abdominal fluid.
• Patients with more than 500 ml of drainage in the 24 hours on postoperative day 4.
• Patients presenting with any of the following clinical signs or diagnoses:

• Postoperative pancreatic fistula (POPF), defined as drain amylase levels (Drain amylase; D-amy) more than 3 times higher than serum amylase levels (Serum amylase; S-amy).
• Fever exceeding 37.8℃.
• Presence of any of the following clinical markers of inflammation:

i. White blood cell count (WBC) > 15,000/μL ii. C-reactive protein > 200 mg/L

• Observation of non-serous drainage fluid, such as:

i. Chylous fluid: Milky-colored fluid. ii. Bloody or sanguineous fluid: Intra-abdominal fluid suggestive of ongoing hemorrhage.

• Vulnerable subjects will not be enrolled in the study, including minors, pregnant women, neonates, adults with impaired consent capacity, individuals in institutional facilities, students, employees of medical institutions or research centers, pharmaceutical company employees, military personnel, unemployed persons, impoverished individuals, homeless individuals, terminally ill patients, or patients in emergency situations.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

South Korea · 1 center

• Gangnam Severacne Hospital Yonsei University College of Medicine — Seoul

Identifiers

NCT: NCT06690112 · 3-2023-0393

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗